Submission of Matters to a Vote of Security Holders.



On May 31, 2023, Context Therapeutics Inc. ("the Company") held its 2023 Annual
Meeting of Stockholders (the "Annual Meeting"). As of April 3, 2023, the record
date for the Annual Meeting, there were 15,966,053 shares of Company common
stock issued and outstanding and entitled to vote on the proposals presented at
the Annual Meeting, of which 10,169,489, or approximately 63.69%, were present
or represented by proxy, which constituted a quorum. The holders of shares of
Company common stock are entitled to one vote for each share held. Set forth
below are the final voting results for the proposals submitted to a vote of the
Company's stockholders at the Annual Meeting, which were described in the
Company's definitive proxy statement filed with the Securities and Exchange
Commission on April 6, 2023. No other matters were considered or voted upon at
the meeting.

Proposal 1. To ratify the selection by the Audit Committee of the Board of Directors of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.

The Company's stockholders ratified the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting on this proposal is set forth below:



                                  For                  Against               Abstentions              Broker Non-Votes
Ratification of                9,827,096               232,432                 109,961                      ---
CohnReznick LLP

Proposal 2. To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of its outstanding common stock at a reverse stock split ratio ranging from any whole number between 1-for-2 and 1-for-50, subject to and as determined by the Board of Directors.

While proposal 2 received the affirmative vote of a majority of the shares present or represented by proxy at the Annual Meeting, the proposal was not approved because stockholders holding a majority of the outstanding shares of Company common stock entitled to vote did not vote "FOR" the proposal. The voting on this proposal is set forth below:



                                    For                  Against               Abstentions              Broker Non-Votes
Amendment to the Company's       7,809,550              2,326,090                 33,849                      ---
Amended and Restated
Certificate of
Incorporation to effect a
reverse stock split

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses